Bluyssen H

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4582693/publications.pdf Version: 2024-02-01



RILIVSSEN H

#	Article	IF	CITATIONS
1	SINBAD, structural, experimental and clinical characterization of STAT inhibitors and their potential applications. Scientific Data, 2022, 9, 139.	5.3	1
2	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Frontiers in Immunology, 2022, 13, .	4.8	29
3	From Transcriptome to Behavior: Intranasal Injection of Late Passage Human Olfactory Stem Cells Displays Potential in a Rat Model of Parkinson's Disease. ACS Chemical Neuroscience, 2021, 12, 2209-2217.	3.5	7
4	Inflammatory Response Leads to Neuronal Death in Human Post-Mortem Cerebral Cortex in Patients with COVID-19. ACS Chemical Neuroscience, 2021, 12, 2143-2150.	3.5	50
5	ESR Method in Monitoring of Nanoparticle Endocytosis in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4388.	4.1	7
6	Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods. Scientific Reports, 2019, 9, 8575.	3.3	19
7	Editorial: STATs and IRFs in Innate Immunity: From Transcriptional Regulators to Therapeutic Targets. Frontiers in Immunology, 2019, 10, 1829.	4.8	1
8	Signal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NFI⁰B to Enhance Pro-inflammatory Transcription. Frontiers in Immunology, 2019, 10, 1253.	4.8	34
9	Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs. Frontiers in Immunology, 2018, 9, 2141.	4.8	7
10	A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses. Frontiers in Immunology, 2018, 9, 1135.	4.8	222
11	Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates. Molecular Cancer, 2018, 17, 116.	19.2	48
12	Genetic characterization of Polish ccRCC patients: somatic mutation analysis of <i>PBRM1</i> , <i>BAP1</i> and <i>KDMC5</i> , genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. Oncotarget, 2017, 8, 28558-28574.	1.8	8
13	Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. Oncotarget, 2016, 7, 48788-48812.	1.8	60
14	Letter to the Editor. Cytokine and Growth Factor Reviews, 2016, 32, 1.	7.2	0
15	The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine and Growth Factor Reviews, 2016, 29, 71-81.	7.2	106
16	STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential. International Reviews of Immunology, 2016, 35, 434-454.	3.3	33
17	Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases. Current Protein and Peptide Science, 2016, 17, 135-146.	1.4	10
18	Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma. Journal of Cancer, 2015, 6, 1105-1113.	2.5	35

Bluyssen H

#	Article	IF	CITATIONS
19	Identification of STAT1 and STAT3 Specific Inhibitors Using Comparative Virtual Screening and Docking Validation. PLoS ONE, 2015, 10, e0116688.	2.5	32
20	CAVS—Novel in silico selection strategy of specific STAT inhibitory compounds. Journal of Computational Science, 2015, 10, 186-194.	2.9	5
21	A theoretical antioxidant pharmacophore for natural hydroxycinnamic acids. Open Chemistry, 2015, 13,	1.9	35
22	STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochemical Journal, 2015, 466, 511-524.	3.7	83
23	Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. BMC Cancer, 2015, 15, 518.	2.6	105
24	STAT2-directed pathogen responses. Oncotarget, 2015, 6, 28525-28526.	1.8	5
25	STAT1-Dependent Signal Integration between IFNγ and TLR4 in Vascular Cells Reflect Pro-Atherogenic Responses in Human Atherosclerosis. PLoS ONE, 2014, 9, e113318.	2.5	63
26	Data Mining of Atherosclerotic Plaque Transcriptomes Predicts STAT1-Dependent Inflammatory Signal Integration in Vascular Disease. International Journal of Molecular Sciences, 2014, 15, 14313-14331.	4.1	24
27	Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in l-NAME-induced hypertension. Cardiovascular Research, 2014, 101, 464-472.	3.8	61
28	FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data. Tumor Biology, 2014, 35, 2607-2617.	1.8	34
29	Comparative screening and validation as a novel tool to identify STAT-specific inhibitors. European Journal of Pharmacology, 2014, 740, 417-420.	3.5	7
30	Molecular Properties and Medical Applications of Peptide Nucleic Acids. Mini-Reviews in Medicinal Chemistry, 2014, 14, 401-410.	2.4	10
31	Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Letters, 2013, 341, 111-126.	7.2	101
32	In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. European Journal of Pharmacology, 2013, 720, 38-48.	3.5	26
33	A type I IFN–Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. Journal of Experimental Medicine, 2013, 210, 2515-2522.	8.5	47
34	STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNÎ3, TLR4 and IL-6 in vascular disease. Cytokine and Growth Factor Reviews, 2011, 22, 211-219.	7.2	80
35	STAT1-mediated signal integration between IFNÎ ³ and LPS leads to increased EC and SMC activation and monocyte adhesion. American Journal of Physiology - Cell Physiology, 2011, 300, C1337-C1344.	4.6	46
36	IFNÎ ³ -dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. American Journal of Physiology - Cell Physiology, 2010, 299, C354-C362.	4.6	56

Bluyssen H

#	Article	IF	CITATIONS
37	Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality. European Journal of Pharmacology, 2009, 602, 163-167.	3.5	13
38	Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. European Journal of Pharmacology, 2008, 593, 99-104.	3.5	20
39	Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats. Physiological Genomics, 2007, 28, 158-167.	2.3	21
40	Anti-oxidant sensitivity of donor age-related gene expression in cultured fibroblasts. European Journal of Pharmacology, 2006, 542, 154-161.	3.5	12
41	Gene expression of energy and protein metabolism in hearts of hypertensive nitric oxide- or GSH-depleted mice. European Journal of Pharmacology, 2005, 513, 21-33.	3.5	8
42	Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT ₂ receptor. American Journal of Physiology - Renal Physiology, 2005, 288, F1191-F1200.	2.7	40
43	Nitric Oxide–Dependent and Nitric Oxide–Independent Transcriptional Responses to High Shear Stress in Endothelial Cells. Hypertension, 2005, 45, 672-680.	2.7	29
44	Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension Is Absent During Treatment. Hypertension, 2004, 43, 947-951.	2.7	73
45	Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1α-hydroxylase knockout mice. Kidney International, 2004, 65, 531-539.	5.2	59
46	Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Letters, 2004, 556, 137-142.	2.8	47
47	Rapid determination of adenoviral vector titers by quantitative real-time PCR. Journal of Virological Methods, 2001, 93, 181-188.	2.1	65
48	Human and Mouse Homologs of theSchizosaccharomyces pombe rad17+Cell Cycle Checkpoint Control Gene. Genomics, 1999, 55, 219-228.	2.9	19
49	Regulation of Interferon-α Responsiveness by the Duration of Janus Kinase Activity. Journal of Biological Chemistry, 1997, 272, 21872-21877.	3.4	86
50	Stat2 Is a Transcriptional Activator That Requires Sequence-specific Contacts Provided by Stat1 and p48 for Stable Interaction with DNA. Journal of Biological Chemistry, 1997, 272, 4600-4605.	3.4	135
51	ISGF3γ p48, a specificity switch for interferon activated transcription factors. Cytokine and Growth Factor Reviews, 1996, 7, 11-17.	7.2	129
52	Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5645-5649.	7.1	143
53	Isolation, properties and chromosomal localization of four closely linked hamster interferon-alpha-encoding genes. Gene, 1995, 158, 295-300.	2.2	4
54	The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility. FEBS Journal, 1994, 220, 395-402.	0.2	35

#	Article	IF	CITATIONS
55	Structure, Chromosome Localization, and Regulation of Expression of the Interferon-Regulated Mouse Ifi54/Ifi56 Gene Family. Genomics, 1994, 24, 137-148.	2.9	56